Mérieux Equity Partners and Korys announce the launch of OMX Europe Venture Fund, dedicated to Venture investment within the healthcare and nutrition sectors.
- Mimetas is a leader in the rapidly growing “organ-on-a-chip” market. Using its OrganoPlate® technology, Mimetas develops and commercializes 3D cell culture models, including tools that facilitate the discovery and development of new therapies;
- MRM Technologies is a company specialized in research & development and dedicated to the microbiome. Its affiliated company ProDigest is a CRO specialized in intestinal microbiome analysis, servicing international clients in the Food & Pharma industry. Its affiliate MRM Health develops innovative therapeutics for the treatment of immune andmetabolic diseases;
- Inscripta commercializes a revolutionary genome editing platform, Onyx™, offering new methods of genome engineering for cutting-edge applications in fundamental research and in various industries;
- TARA Biosystems offers in vitro cardiac models for the pharmaceutical industry - using induced Pluripotent Stem Cells (iPSCs) - that are more predictive in terms of efficacy and toxicity and help accelerate the development of new therapies.
About Mérieux Equity Partners – www.merieux-partners.com
Mérieux Equity Partners is a management company registered with the Autorité des Marchés Financiers (AMF) since June 2018 that is dedicated to growth equity and venture capital investments. Mérieux Equity Partners currently operates with an international team of 20 employees and regional partners – based in Europe and North America. With over EUR 650 million under management, Mérieux Equity Partners actively supports entrepreneurs and industrial companies whose products and services bring differentiated and innovative solutions in the healthcare and nutrition sectors by providing privileged access to its expertise and the industrial, scientific and commercial network of Institut Mérieux, in compliance with the current regulations.
About Korys – www.korys.be
Korys is the investment company of the Colruyt family. Today, it has more than EUR 4.5 billion of assets under management. Besides holding a significant participation in the Colruyt Group, a leading retail company in Belgium and France, it actively manages participations in privately held companies and in private equity funds. Korys has also set up proprietary funds to manage its portfolio of listed investments. Across its activities, Korys’ investment decisions are taken with a long-term perspective and on basis of strict economic (Profit), social (People) and ecological (Planet) criteria. Korys aims to create sustainable value in three major ecosystems: Life Sciences, Energy Transition and Conscious Consumer. To do this, Korys can count on a motivated team of 30 professionals based in Belgium and Luxembourg.